MaxCyte gets US FDA clearance to begin clinical study of CAR therapeutic candidate, MCY─M11

MaxCyte, a global cell─based medicines and life sciences company, has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to begin a clinical study in the United

More From BioPortfolio on "MaxCyte gets US FDA clearance to begin clinical study of CAR therapeutic candidate, MCY─M11"